NeoCytex BioPharma neocytex.com/index.html


Public lists: Pharma Startups (4732)

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascu...Show all

Company (Alive / Active)

Phone:

Fax:

Lexington, 32801
Kentucky, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
NeoCytex BioPharma $0M Nov 30, 2018
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related NeoCytex BioPharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Alvine Pharmaceuticals

San Carlos, California, United States
Alive / ActiveAlvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protea...Show allLogin to see details

CoMentis

South San Francisco, California, United States
Alive / ActiveCoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum from initial drug design through manufacturing and clinical trials.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)